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Abstract.  p-Nitrobenzyloxycarbonyl was used as temporary protecting group for the α-amino function 
in solid-phase peptide synthesis.  The corresponding derivatives are solids, easy to be synthesized, and 
perform well in the solid-phase mode.  pNZ is removed in practical neutral conditions in the presence of 
catalytic amounts of acid. They are orthogonal with the most common protecting groups used in peptide 
chemistry. They are specially useful in combination with Fmoc chemistry to overcome those side 
reactions associated with the used of the piperidine such DKP and aspartiimide formation.  The 
flexibility of pNZ can be very useful for the preparation of libraries of small organic molecules.  
 
Keywords. Orthogonal protecting group, Nitro reduction, Side-reactions, combinatorial chemistry. 
Introduction 
The development of the solid-phase methodology for the preparation of peptides carried by Bruce R. 
Merrifield1 in the late fifties and early sixties has been crucial for positionating  peptides as important 
biochemical tools and, more important, to play an important role in several therapeutic areas.2  
Nowdays, more than 40 peptides are into the market, 4 more in registration, 200 in clinical phases, and 
more of 400 in advanced preclinical.3   
Solid-phase peptide synthesis (SPPS) strategies come dictated by the lability of both the temporary 
(for the Nα-amino function) and the permanent (for side-chain functions and for the anchoring of the C-
terminal to the solid support trough the handle) protecting groups.4  The seminal SPPS strategy proposed 
by Merrifield and fine tuned over the years is based on a graduated acid lability of the tert-
butyolxycarbonyl (Boc) as temporary group, which is removed by trifluoroacetic acid (TFA) usually 25-
50% in CH2Cl2; and benzyl type permanent protecting groups, which are removed by strong acids, such 
as anhydrous HF or trifluoromethanesulfonic acid.4    Although the Boc based method has been showed 
to be successful for the preparation of large number of peptides, the long exposure of the peptide chain 
to TFA in the removal of the Boc group can also cause premature removal of the benzyl protecting 
group.  Furthermore some fragile residue containing peptides do not survive the relatively harsh acid 
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conditions.  Finally, HF can be considered a dangerous gas that requires to be treated in an special 
Teflon reactor.  All these have fuelled the development of milder strategies avoiding the use of the harsh 
acid conditions.  Thus, nowdays most of the peptides are prepared using the Fmoc−t-butyl strategy.4,5 
This has the additional advantage of being an orthogonal scheme6 as the Fmoc (temporary group) is 
removed by piperidine usually 20% in N,N-dimethylformamide (DMF) and the permanent protecting 
groups are removed by high percentages of TFA in the presence of scavengers.  Thus, the selective 
deprotection is governed by alternative cleavage mechanism rather than by reaction rates.  Although this 
has become the strategy of choice for the preparation of peptides, the preparation of complex molecules 
such as cyclic or branched systems could require the use of other protecting groups.7  Furthermore, the 
conditions used to remove the Fmoc group are still, in some cases, too harsh and can be incompatible 
with several sequences.  The main drawbacks associated with the use of the Fmoc are that both the 
piperidine, which is a base and a rather good nucleophile, and the free amine that is formed can provoke 
some side reactions.   Thus, an optimal group for the protection of the Nα-amino function as alternative 
to the Fmoc group should be removed in practical neutral conditions and the deprotection step should 
left the amine function masked to prevent side reactions.  In addition, the protecting group should be 
orthogonal with t-butyl based protecting groups and others such as the allyl based and the same Fmoc if 
they should be used for the preparation of complex peptides or other organic molecules.    
Herein, the use of the p-nitrobenzyloxycarbonyl (pNZ) (Figure 1) group for the temporary protection 
of the α-amino function in a SPPS strategy is reported.   
CH2O2N O
O
pNZ
 
Figure 1.  Structure of pNZ protecting group 
The pNZ group, which is a carbamate type protecting group, was first described by Carpenter and 
Gish as an alternative to the benzyloxycarbonyl (Z).8  Furthermore, it has been used for the protection of 
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the ε-amino function of Lys.9  The related  p-nitrobenzyl (pNB) group has been used in peptide synthesis 
for the protection of the C-terminal carboxylic function in side-chain anchoring strategies  for the SPS of 
head-to-tail cyclic peptides,10 and for another function in classical organic chemistry.11   
Results and Discussion 
Preparation of p-nitrobenzyloxycarbonyl(pNZ)-amino acids 
The classical method for the preparation of Nα-carbamate protected amino acids is through the 
corresponding and reactive chloroformate reagents under Schotten-Baumann conditions, which can lead 
to the formation of protected dipeptides as side products.12  This high incidence of protected dipeptide 
can lead to the insertion of an extra amino acid in the final peptide synthesis, which cannot be tolerated 
for use in therapeutic applications.  Several approaches based on the use of different activated formates 
have been proposed to minimize this problematic side reaction.13  An efficient, competitive and 
inexpensive procedure is the azide method.12,14,15 In this case, an optimized one-pot protocol based on 
the azide, which was recently described, was used.13  pNZ-Cl reacts with NaN3 and without isolating the 
pNZ-N3, the reaction with the free amino acids leads to the pNZ-amino acids.  These derivatives, which 
were obtained in relatively high yields (71-94%) and purity, were characterized by HPLC, IR, 1H/13C-
NMR, and HRMS.  
Solubility of pNZ – and Fmoc-amino acids 
A good solubility of the protected amino acids is important for running reactions at high concentration 
and for facilitating the use of these derivatives in an automatic mode, which is a technique very used for 
SPPS.  In this regards, pNZ derivatives have shown to present superior solubility in DMF to the 
corresponding Fmoc-derivatives (Table 1). 
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Table 1.  Solubility comparison of pNZ-aa-OH versus to 
Fmoc derivatives 
Amino Acid Solubility in DMFa (g/mL) 
pNZ-L-Phe-OH 0.80 
Fmoc-L-Phe-OH 0.31 
pNZ-L-Gly-OH 1.33 
Fmoc-L-Gly-OH 0.80 
pNZ-L-Asp(OtBu)-OH 1.00 
Fmoc-L-Asp(OtBu)-OH 0.67 
aAll derivatives except pNZ-L-Asp(OtBu)-OH  show negligible solubility in CH2Cl2. 
Removal of the pNZ group 
The pNZ can be removed by catalytic hydrogenation and other reducing agents of the nitro group.  In 
this case, the first step is the reduction of the nitro group to give the p-aminobenzylozycarbonyl 
derivative, which suffers a spontaneous collapse via 1,6-electron pair shift to render the quinonimine 
methide and the carbamic acid.  Finally, this decomposes to give the free amine (Figure 2).16  If this 
process is carried out in the presence of catalytic amounts of an acid, the ammonium salt is obtained.    
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Figure 2.  Mechanism for the removal of the pNZ group 
 
As it is shown in Figure 2, the key step in the pNZ removal process is the reduction of the nitro group 
to the corresponding amino. Although the most common method for this functional group 
interconversion is catalytic hidrogention,17 it is not useful for SPPS. Other common methods are the use 
of metals such as Zn,11b Fe,18 or Sn18 in acidic solutions, but the use of this chemistry for the present 
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purposes has two main problems: (i) the difficulty in working with metals on solid phase and (ii) the 
strong acidic conditions required.  Finally, two reagents, Na2S2O419  and SnCl2,8b,20,21 which in principle 
could be compatible with solid phase synthesis were essayed.    
Na2S2O4 
Although Na2S2O4 is a good reductor of nitro groups in basic medium,22 there are also described 
several applications of its use in neutral or nearly neutral medium.19  
The main problem for the use of Na2S2O4 in solid-phase in its solubility.  Thus, Na2S2O4 is very 
insoluble in DMF and other solvents that swells well the resin.  Furthermore, Na2S2O4 for reducing the 
nitro groups needs H2O, which is not a good solvent for the most of solid supports.  To try to overcome 
that, 15-Crown-5 was used to solubilize the Na2S2O4.  First of all, several attempts of removing the pNZ 
group of pNZ-Orn(Boc)-OH in solution were carried out varying the amounts of water and 15-Crown-5.  
It was found by TLC (CONDITIONS) that the rate of cleavage increases with the the concentration of 
H2O and 15-Crown-5  
SnCl2 is a good reductor of nitro group in the presence of catalytic amounts of acid. The first acid 
tested was HOAc, but for preventing acetilation of the amino fucntion, other non carboxylic acids were 
tested directly in solid-phase.  
pNZ-Phe-Gly-Gly-Ley-NH-Rink-polystyrene resin was used as a model.  Removal of the pNZ group 
were carried out in different conditions using both Na2S2O4 and SnCl2 as reducing agents and the peptide 
crude was analyzed by HPLC (Table 2).     
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     Table 2.  Removal of pNZ group from pNZ-Phe-Gly-Gly-Ley-NH-Rink-polystyrene resin 
Entry Removal Conditionsa  T(ºC) Time (min)  %b 
1 1M Na2S2O4 in H2O-AcCN-EtOH (1:1:1) rt 360 0 
2 1M Na2S2O4  and 15-Crown-5 in DMF−H2O (9:1)  rt 60 11 
3 1M  Na2S2O4  and 15-Crown-5 in DMF−H2O (9:1)  rt 420 35 
4 1M Na2S2O4, 15-Crown-5, and DIEA in DMF−H2O (9:1) rt 60 12 
5 1M Na2S2O4, 15-Crown-5, and DIEA in DMF−H2O (9:1) rt 420 13 
6 8 M SnCl2, 1.6 mM AcOH, 0.04 M phenol  in DMF rt 60 91 
7 8 M SnCl2, 1.6 mM AcOH, 0.04 M phenol  in DMF rt 300 100 
8 6 M SnCl2, , 0.04 M phenol  in DMF−TFE (19:1) rt 60 68 
9 6 M SnCl2, 0.04 M phenol  in DMF−TFE (19:1) rt 300 100 
10 6 M SnCl2, 0.04 M phenol  in DMF−HFIP (19:1) rt 60 76 
11 6 M SnCl2, 0.04 M phenol  in DMF−HFIP (19:1) rt 300 100 
12 6 M SnCl2,1.6 mM TosOH, 0.04 M phenol  in DMF rt 60 86 
13 6 M SnCl2,1.6 mM HCl/dioxane, 0.04 M phenol  in DMF rt 60 93 
14 6 M SnCl2,1.6 mM HCl/dioxane, 0.04 M phenol  in DMF rt 2 x 30 98 
15 6 M SnCl2, 64 mM HCl/dioxane in DMF rt 2 x 10 58 
16 6 M SnCl2, 64 mM HCl/dioxane in DMF rt 2 x 20 85 
17 6 M SnCl2, 64 mM HCl/dioxane in DMF rt 2 x 30 97 
18 6 M SnCl2,1.6 mM HCl/dioxane, 0.04 M of phenol  in 
DMF 
50 ºC 2 x 10 97 
19 6 M SnCl2,1.6 mM HCl/dioxane, 0.04 M of phenol in 
DMF 
50 ºC 2 x 20 100 
   aExperiments were carried out with 10 mg of resin and 0.5 mL of solvent; bYield was calculated by 
comparison between the areas of the HPLC peaks corresponding to the protected and the deprotected 
peptides, as the ε of the unprotected peptide should be lower than the one of the protected, these yields 
are really higher than expressed.  
 
The data outlined in Table 2 show that SnCl2 based method is superior to the one based on Na2S2O4. 6 
M SnCl2 solution is more convenient than 8 M, because in this case the solution is supersaturated  and 
some solid SnCl2 can come off (GREG ES CORRECTO? QUEREMOS DECIR QUE PUEDE 
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APARECER UN SOLIDO).  HCl (entry 13) is slightly superior to  Tos-OH (entry 12) and AcOH (entry 
6), while the performance of acid alcohols [HFIP (entry 10), TFE(entry 8)] are inferior.   
As HCl is the best and can not produce capping on the free amine, this is the acid recommended.  The 
increase of the concentration of the HCl from 1.6 mM (entry 16) to 64 mM (entries 18 and 19) does not 
improve the rate of deprotection.  The presence of phenol does not increase neither the rate of 
deprotection nor the purity of the final product.  As it can be expected, a higher temperature, 50 ºC 
(entry 21) increases the deprotection rate when compared with rt.     
Orthogonality of pNZ-amino acids in front of Fmoc, Boc, and Alloc groups  
The preparation of complex peptides such as cyclic, branched, or those containing chemical fragile 
motives require very often the presence of orthogonal protecting groups.6,7  To show the orthogonality of 
pNZ-amino acids in front of the most common protecting groups, samples of pNZ-Xx-OH were 
dissolved in piperidine-DMF (1:4) and TFA (9:1) and after 2 h, the TLC showed that the pNZ-amino 
acids are totally stable in the presence of those reagents.  Likewise, pNZ-Xx-OH showed to be also 
stable in the presence of Pd(0) (CONDICIONES DE ELIMINAR ALLOC).  Furtermore, Boc-Xx-OH, 
Fmoc-Xx-OH, and Alloc-Xx-OH resulted to be stable to 6 M SnCl2,1.6 mM HCl(dioxane), in DMF for 
2 h. These data confirms that the pNZ group is orthogonal in front of Boc, Fmoc, and Alloc protecting 
groups.  
Solid-Phase Peptide Synthesis Using a pNZ/tBu strategy  
Using pNZ-amino acids with t-butyl side chain protecting groups, Leu-enkephalinamide and human 
phospholipase A2 (18-23) were synthesized on a Rink-resin.   
Two parallel syntheses of H-Tyr-Phe-Gly-Gly-Leu-NH2 (Leu-enkephalinamide) were carried out. 
Removal of the pNZ group was carried out with 6 M SnCl2,1.6 mM HCl/dioxane in DMF (2 x 30 min) 
at room temperature and at 50 ºC, followed by extensive washings with DMF (3 x 30 s), DMF−H2O (3 x 
30 s), THF−H2O (3 x 30 s), DMF (3 x 30 s), and DCM (3 x 30 s) to remove the excess of  SnCl2 as well 
as the side products coming from the protecting group. Before coupling the following pNZ-amino acid, 
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the resin was neutralizated with diisopropylethylamine (DIEA)−CH2Cl2 (1:9).23  Couplings were 
performed using a N,N-diisopropylcarbodiimide (DIPCDI) and 1-hydroxybenzotriazole (HOBt) 
mediated method.  After removal of the last pNZ group, free peptides were released from the resin by 
acidolytic cleavage [TFA−H2O−DCM (90:5:5)] and worked-up.  Both crude products give a good purity 
by HPLC (Figure 3a) and a correct HPLC-MS.   ALGUNA DIFERENCIA ENTRE LAS DOS 
SINTESIS. 
Figure 3.  HPLCs of peptides 
Synthesis H-Ala-Leu-Ser-Tyr-Gly-Phe-NH2 [human Phospholipase A2 (18-23)] was carried out 
similarly as outlined above.  The pNZ was removed at room temperature, and the couplings were carried 
out using a 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]pyridinium hexafluorophosphate 
3-oxide (HATU)/DIEA mediated method.  In this case the neutralization step was omitted.  After final 
acidolytic cleavage and work-up the crude peptide shown a good purity by HPLC (Figure 3b) and a 
correct HPLC-MS.  
Use of  the pNZ group to Circumvent Problems Associated with Fmoc Chemistry 
As mentioned above, the main drawback associated with the Fmoc strategy is related with the use of 
piperidine, which is an excellent  nucleophile and a medium strength base.  Furthermore, after removal 
of the Fmoc group, the amino function remains as a free amine.  Both, the piperidine and the free amine 
can cause side reactions such as the formation of  diketopiperazines (DKP) and aspartiimides in the case 
of Asp containing peptides.  
DKP Formation 
The solid-phase synthesis of peptide C-terminal acids sometimes requires special protocols for the 
incorporation of the second and third amino acids.  In the absence of these, the free amino group of the 
resin-bound dipeptide can attack the peptide-resin anchorage intramolecularly giving rise to cyclic 
dipeptides or DKPs.4a,24   
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Figure 4. DKP formation mechanism 
 
Although DKP formation is governed by different factors,25 this side-reaction is mores severe in a 
Fmoc strategy than in a Boc one. First of all, piperidine catalyzes the side reaction,26  and, secondly, the 
removal of the Boc group is carried out in acid medium, so the amine function remains protonated and 
the incorporation of the third Boc-amino acid can  be done with neutralization in situ, which minimizes 
the DKP formation.27 In Fmoc chemistry, DKP formation can be minimized using resins with large 
steric hindrance such as those based on trityl (Trt) or t-Bu groups28 or by incorporation of the second 
residue with Trt protection and then after removal of the Trt group in acid medium, to carry out the 
incorporation of the third residue with neutralization in situ.29  In mild conditions, DKP can be also 
minimized by incorporation of the second amino acid protected with the Alloc group in conjunction 
with a tandem deprotection-coupling reaction, which it is carried out with the corresponding fluoride 
derivative and it is more facile than DKP formation.30   
The pNZ as is removed in practical neutral conditions with catalytic amounts of an acid is a good 
candidate to be used for the protection of the second amino acid in order to prevent or minimize the 
DKP formation.  To demonstrate this methodology, the tripeptide H-Phe-D-Val-Pro-OH was chosen as a 
model. Thus, pNZ-D-Val-Pro-AB-Leu-aminomethylresin and Fmoc-D-Val-Pro-AB-Leu-
aminomethylresin were synthesized with Fmoc-Pro-OH and pNZ/Fmoc-D-Val-OH, using a  Leu residue 
as internal reference amino acid (IRAA) to calculate the yield.31  While 100% of DKP formation was 
detected after removal of the Fmoc group of the D-Val residue [piperidine−DMF (2:8)] and 
incorporation of the Fmoc-Phe-OH, no DKP was observed in the case of the pNZ peptide resin.  In this 
case, the pNZ was removed with 6 M SnCl2,1.6 mM HCl(dioxane) in DMF (2 x 30 min) at room 
temperature and after extensive washings, the Fmoc-Phe-OH (5 equiv) was incorporated in the presence 
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of 7-azabenzotriazol-1-yl-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) (5 equiv) 
and DIEA (10 equiv) with neutralization in situ.32   
Aspartimides formation 
The cyclization of Asp residues to form aspartimides is a common side reaction in peptide 
synthesis.4a,33  Although, this side reaction is favoured in different conditions (strong acids, excess of 
coupling reagents and basic medium) and depends of the sequence, it is more important when a Fmoc 
strategy is used due to the repetitive treatment with piperidine.  In this case, at the end of the synthetic 
process besides of the aspartimide containing peptide, it can be found α- and β-peptides (coming from 
the hydrolysis of the α-imide) and the α- and β-piperidides coming from the attack of piperidine on the 
aspartiimide.    
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Figure 5.  Aspartiimide formation mechanism and side products that  can be obtained from the aspartiimide 
The side reaction is more severe when the β-carboxyl group of the Asp is protected with the allyl 
group, due to be a better leaving group than t-Bu.34   Although, the side reaction can try to be minimized 
when hindered protecting groups35  for the Asp are used and when the previous amide is protected,36 a 
more convenient and general method is needed. 
A combination of Fmoc, until the incorporation of the Asp residue, and pNZ for the Asp and the 
following amino acids can solve this problem, because the removal of the pNZ group does not require 
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the repetitive presence of a base and at the end of the synthetic process the final cleavage and 
deprotection is carried out with TFA, which is less prone to give aspartimide than HF used in a Boc/Bzl 
chemistry strategy.4a 
The peptide H-Ala-Orn-Asp-Gly-Tyr-Ile-NH2 was chosen as a model, because it contains the 
sequence Asp-Gly-Tyr-Ile, which is considered to give a large amount of aspartiimides.33b    Two 
parallel syntheses were carried out on a Rink-resin. The first one, Fmoc protection was used for Ile, Gly, 
and Gly, and pNZ for Orn(Boc) and Ala.  Fmoc-amino acids were only used for the second.  
Furthermore, the peptide H-Ala-Orn-Asp(Gly-Tyr-Ile-NH2)-OH37 was synthesized, using Fmoc 
chemistry, because it can be one of the side products if aspartimide is formed. Fmoc and pNZ peptides 
were treated 4h with piperidine 20% in DMF and 6M SnCl2 in DMF respectively. While that both 
piperidides were detected in the synthesis carried out with only Fmoc-amino acids, no aspartimide 
neither β-peptide were observed in the synthesis carried out with a combination of pNZ and Fmoc.   
Conclusions 
This work has demonstrated the benefits of using pNZ as temporary protecting group for the α-amino 
function in SPPS.  The corresponding derivatives are easy to be synthesized and in contrast as other α-
amino protecting groups such as Trt and Alloc, they are solids. pNZ is removed in practical neutral 
conditions in the presence of catalytic amounts of acid.  pNZ is orthogonal to the most common 
protecting groups such as t-Bu/Boc, Fmoc, and Alloc.  Besides to be used for the total elongation of the 
peptide chain, it can be used in combination with Fmoc chemistry to overcome those side reactions 
associated with the used of the piperidine such DKP and aspartiimide formation.  It is also predictable 
(GREG en castellano, predecible) that the use of pNZ will avoid the formation of N-piperidylalanine 
residue during the preparation of C-terminal Cys peptides as occurs in the Fmoc strategy.38  The 
flexibility of pNZ can be very useful for the preparation of libraries of small organic molecules.  
Experimental section 
General procedures: Commercial-grade reagents and solvents were used without further purification. 
Resins, linkers and amino acid derivatives, HOBt, DIPCDI, PyAOP, HATU, p-nitrobenzyl 
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chloroformate and sodium azide were obtained from NovaBiochem (Laüfelfingen, Switzerland), 
Bachem (Bubendorf, Switzerland), Iris Biotech (Marktredwitz, Germany), Aldrich (Milwaukee, WI), 
Acros (Geel, Belgium), Neosystem (Strasbourg, France), and Luxembourg Industries (Tel Aviv, Israel). 
Analytical HPLC was carried out on a Waters instrument comprising two solvent delivery pumps and 
automatic injector (Waters Separations Module 2695) and a variable wavelength detector (model Waters 
996 Photodiode Array). UV detection was performed at 220 nm, and linear gradients of CH3CN 
(0.036% TFA) into H2O (0.045% TFA) were run at 1.0 mL flow rate. MS-HPLC was carried out on a 
Waters instrument comprising two solvent delivery pumps and automatic injector (Waters Separations 
Module 2795), a dual wavelength detector (Waters 2487, Dual λ Absorbance Detector) and an 
electrospray detector (Waters micromass ZQ).  
Amino Acid Analyses were performed using a Beckman System 6300 High Performance Analyzer. 
Resins were treated with a mixture of HCl and propionic acid (1:1) for 1h at 160ºC, and after 
evaporating the acid under reduced pressure, they were suspended in amino acid analysis buffer and 
filtered. 
pNZ-Amino Acid Synthesis  
Method 1:  
p-Nitrobenzyl chloride (1.73g, 8 mmol) was dissolved in 1,4-dioxane (3.5 mL) and a solution of 
sodium azide (0.624g, 9.6 mmol) in H2O (2.5 mL) was added. The resulting emulsion was stirred for 2 
h. and the formation of the azide can be followed by TLC (DCM).  Then, Gly (0.600 g, 8 mmol) 
dissolved in 1,4-dioxane−2% aqueous Na2CO3 (1:1) (10 mL) was added dropwise and the resulting 
white suspension was stirred for 24 keeping the pH between 9-10 by adding 10% aquous Na2CO3.  After 
this time, TLC (CH2Cl2) showed that there was not azide left, then H2O (75 mL) was added and  the 
suspension was washed with tert-butyl methyl ether (BME) (3 x 40 mL). The aqueous portion was 
acidified to pH 2-3 with 12 N HCl−H2O (3:1), when a white precipitate appeared, which was filtered off 
and dried to yield 1.44g (71 % of yield) of the title compound as  white solid.   
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Method 2:  
The synthesis was performed as in Method 1 but the acidic suspension was extracted with AcOEt. The 
organic layers were dried on MgSO4, filtered, and the solvent was removed under reduced pressure to 
yield an oil, which solidified as with solid by washing with diethyl ether or suspended in acetonitrile 
(AcCN)−H2O and liofilized (H-D-Val-OH and H-L-Ala-OH). The pNZ-amino acids were recrystalized 
in H2O or in diethylether−hexane. 
All protected amino acids were characterized by HPLC (Gradient A: from H2O to AcCN; Gradient B: 
from AcCN−H2O (3:7) to AcCN, where H2O contains 0.045 % of TFA and AcCN contains 0.036% of 
TFA), HPLC-MS, 1H and 13C NMR, HR-MS, and IR. 
Amino Acid Leu Ile D-Val Phe Gly Ser(tBu) Orn(Boc) Asp(OtBu) Ala Tyr(tBu) 
Method 2 2 2 1 1 2 2 2 2 1 
Yield (%) 77 94 83 84 71 85 83 89 81 82 
 
pNZ-Ser(tBu)-OH: mp= 92.8-93.8ºC. HPLC rt = 11.28 min.(Gradient A) IR (KBr): ΰ(cm-1) 3364, 
3170, 2980, 1741, 1697. 1H NMR (400 MHz, DMSO) δ 8.21 (2H, d, J= 8.6), 7.61 (2H, d, J = 8.6 Hz), 
7.45 (NH, d, J = 8.3 Hz), 5.18 (2H, s), 4.10(1H, m), 3,55 (2H, m), 1.09 (9H, s). 13C NMR (100 MHz, 
DMSO) δ 172.44 (C), 156.42 (C), 147.60 (C), 128.78 (CH Ar), 124.15 (CH Ar), 73.50 (C), 64.93 (CH2), 
62.03 (CH2), 55.61 (CH), 27.84 (CH3). HRMS (CI) m/z for C15H21N2O7 (M+H+) calcd 341.1350, found 
341.1359. 
pNZ-D-Val-OH: mp= 125.5-127.5 ºC. (12)  HPLC rt = 10.5 min. (Gradient A). IR (KBr): ΰ(cm-1) 
3322, 2970, 1693, 1540 1H NMR (400 MHz, DMSO): δ 8.22 (2H, d, J = 8.6), 7.63 (NH, d, J = 
unresolved),  7.61 (2H, d, J = 8.6 Hz), 5.17 (2H, s), 3.86 (1H, dd, J= 8.5 Hz, J= 5.9 Hz), 2.48 (1H, m), 
0.89 (3H, d, J unresolved), 0,87 (3H, d, J unresolved). 13C NMR (100 MHz, DMSO) δ 173.82 (C), 
156.81 (C), 147.61 (C), 145,76 (C), 128.77 (CH Ar), 124.18  (CH Ar), 64.91 (CH2), 60.30 (CH), 30.23 
(CH), 19.83 (CH3), 18.68 (CH3). HRMS (MALDI-TOF) m/z for C13H16N2O6Na (M+Na+) calcd 
319.0906, found 319.0889. 
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pNZ-Gly-OH: mp= 121.5-122.5 ºC. HPLC rt = 4.50 min. (Gradient B). IR (KBr): ΰ(cm-1): 3383, 
3117, 2941, 1751, 1705, 1522. 1H NMR ( 400 MHz, DMSO) δ 8.21 (2H, d, J =8.7 Hz), 7.70 (NH, t, J = 
6.1 Hz), 7.64 (2H, d, J = 8.7 Hz), 5.18 (2H, s), 3.67 (2H, d, J =6.1 Hz). 13C  NMR (100 MHz, DMSO) δ 
172.12 (C), 156.9 (C), 147.62 (C), 145.7 (C), 128.77 (CH Ar), 124.20 (CH Ar), 64.96 (CH2), 42.84 
(CH2). HRMS (CI) m/z for C10H11N2O6 (M+H+) calcd 255.0618, found 255.0611. 
pNZ-Leu-OH: mp= 81.0-85.5 ºC. HPLC rt = 7.90 min. (Gradient B)  IR (KBr): ΰ(cm-1): 3421.3, 
2961.2,1693, 1524. 1H NMR  ( 400 MHz, DMSO) δ 8.21 (2H, d, J = 8.8 Hz), 7.70 (NH, d, J= 8.2 Hz),  
7.58 (2H, d, J = 8.8 Hz), 5.15 (2H, s), 3.95 (1H, m), 1.63 (1H, m), 1.50 (2H, m), 0.86 (3H, d, J = 6.6 
Hz), 0.82 (3H, d, J = 6.5 Hz). 13C  NMR (100 MHz, DMSO) δ 174.93 (C), 156.55 (C), 147.61 (C), 
145.73 (C), 128.75 (CH), 128.47 (CH), 64.88 (CH2), 52.94 (CH), 40.27 (CH2), 25.00 (CH), 23.54 
(CH3), 21.80 (CH3). HRMS (CI) m/z for C14H19N2O6 (M+H+) calcd 311.1244, found 311.1252. 
pNZ-Ile-OH: mp= 79-83ºC. HPLC rt = 11.21 min. (Gradient A) IR  (KBr): ΰ(cm-1): 3321, 2967, 
1727, 1659, 1538. 1H NMR ( 400 MHz, DMSO) δ 8.22 (2H, d, J = 8.7 Hz), 7.64 (NH, d, J = 8.5 Hz), 
7.61 (2H, d, J = 8.7 Hz), 5.17 (2H, s), 3.90 (1H, dd, J = 8.4 Hz, J’= 6.1 Hz), 2.48 (1H, m), 1.77 (1H, m), 
1.38 (1H, m), 1.20 (1H, m), 0.84 (3H,d, J = 6.8 Hz), 0.81 (3H, t, J = 7.4 Hz). 13C  NMR (100 MHz, 
DMSO) δ 173.84 (C), 156.72 (C), 147.62 (C), 145.76 (C), 128.78 (CH), 124.19 (CH), 64.92 (CH2), 
59.32 (CH), 36.76 (CH), 25.35 (CH2), 16.29 (CH3), 11.95 (CH3). HRMS (MALDI-TOF) m/z for 
C14H18N2O6Na (M+Na+) calcd 333.1063 found 333.1063. 
pNZ-Tyr(tBu)-OH: mp= 130-136.5ºC. HPLC rt = 9.61 min. (Gradient B)   IR (KBr): ΰ(cm-1): 3351, 
2980, 1703, 1522. 1H NMR ( 400 MHz, DMSO) δ 8.18 (2H,d, J = 8.7 Hz), 7.69 (NH, d, J = 8.6 Hz), 
7.45 (2H, d, J = 8.7 Hz), 7.13 (2H, d, J = 8.4 Hz), 6.83 (2H, J = 8.4 Hz), 5.09 (2H, m), 4.15 (1H, m), 
3.04 (1H, dd, Jgem= 13.8 Hz, J = 4.2 Hz), 2.77 (1H, dd, Jgem= 13.8 Hz, J =10.7 Hz), 1.24 (9, JH, s). 
13C  NMR (100 MHz, DMSO) δ 173.99 (C), 156.28 (C), 154.15 (C), 147.51 (C), 145.86 (C),         
133.22 (C), 130.41 (CH), 128.46 (CH), 124.11 (CH), 123.95 (CH), 78.27 (C), 64.62 (CH2), 56.47 (CH), 
36.70 (CH2), 29.21 (CH3). HRMS (CI) m/z for C21H25N2O7 (M+H+) calcd 417.1663, found 417.1665. 
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pNZ-Phe-OH: mp= 129.0-135.1 ºC. HPLC rt = 7.90 min. (Gradient B)  IR (KBr): ΰ(cm-1): 3329, 
1702, 1516. 1H NMR ( 400 MHz, DMSO) δ 8.17 (2H, d, J = 8.7 Hz), 7.76 (NH, d, J = 8.5 Hz), 7.48 
(2H, d, J = 8.7 Hz), 7.25 (5H, m), 5.09 (2H, s), 4.16 (1H, m), 3.08 (1H, dd, Jgem= 13.8 Hz, J = 4.3 Hz), 
2.82 (1H, dd, Jgem= 13.8 Hz, J = 10.6 Hz). 13C  NMR (100 MHz, DMSO) δ 173.89 (C), 156.34 (C), 
147.53 (C), 147.76 (C), 145.76 (C), 138.61 (C), 129.80 (CH), 128.83 (CH), 128.57 (CH), 124.12 (CH), 
64.74 (CH2), 56.33 (CH), 37.20 (CH). HRMS (CI) m/z for C17H17N2O6 (M+H+) calcd 345.1087, found 
345.1079. 
pNZ-Ala-OH: amorfous solid. HPLC rt = 9.28 min. (Gradient A) IR (KBr): ΰ(cm-1): 3348, 1697, 
1530. 1H NMR ( 400 MHz, DMSO) δ 8.21 (2H, d, J = 8.7 Hz), 7.74 (NH, d, J = 7.6 Hz), 7.59 (2H, d, J 
= 8.7 Hz), 5.16 (2H, s), 3.99 (1H, m), 1.26 (3H, d, J = 7.4 Hz). 13C  NMR (100 MHz, DMSO) δ 174.94 
(C), 156.23 (C), 147.61 (C), 145.71 (C), 128.79 (CH), 124.18 (CH), 64.84 (CH2), 49.97 (CH), 17.71 
(CH3). HRMS (MALDI-TOF) m/z for C11H12N2O6Na (M+Na+) calcd 291.0593 found 291.0599. 
pNZ-Orn(Boc)-OH: amorfous solid. HPLC rt = 7.51 min. (Gradient B) IR (KBr): ΰ(cm-1): 1H NMR ( 
400 MHz, DMSO) δ 8.22 (2H, d, J= 8.6 Hz), 7.68 (NH, d, J = 8.0 Hz), 7.60(2H, d, J = 8.6 Hz), 6.77 
(NH, t, J = 4.8 Hz), 5.17 (2H, s), 3.90 (1H, m), 2.91 (2H, m), 1.35 (9H, s). 13C  NMR (100 MHz, 
DMSO) δ 174.40 (C), 156.50 (C), 147.60 (C), 145.77 (C), 128.73 (CH), 124.19 (CH), 78.07 (C), 64.84 
(CH2), 54.45 (CH),  40.09 (CH2), 28.94 (CH3), 28.88 (CH2), 26.87 (CH).  HRMS (CI) m/z for 
C18H26N3O8 (M+H+) calcd 412.1721, found 412.1719. 
pNZ-Asp(OtBu)-OH: mp= 79.5-82.6ºC. HPLC rt = 11.37 min. (Gradient A)   IR (KBr): ΰ(cm-1): 
3342, 3157, 1723, 1699, 1521. 1H NMR ( 400 MHz, DMSO) δ 8.21 (2H, d, J = 8.7 Hz), 7.76 (NH, d, J 
= 8.6 Hz), 7.59 (2H, d, J = 8.7 Hz), 5.17 (2H, s), 4.33 (1H, m), 2.68 (1H, dd, Jgem= 16.0 Hz, J = 5.7 
Hz), 2.52 (1H, dd, Jgem= 16.0 Hz, J = 8.4 Hz), 1.35 (9H, s). 13C  NMR (100 MHz, DMSO) δ 173.03 
(C),  169.87 (C), 156.21 (C), 147.62 (C), 145.62 (C), 128.92 (CH), 124.30 (CH), 80.98 (C), 64.97 
(CH2), 51.32 (CH), 37.88 (CH2), 28.44 (CH3). HRMS (CI) m/z for C16H21N2O8 (M+H+) calcd 369.1299, 
found 369.1309. 
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Solid-Phase Synthesis 
Solid-phase syntheses were carried out in polypropylene syringues (2-10 mL) fitted with a 
polyethylene porous disk.  Solvents and soluble reagents were removed by suction.  
Fmoc: Removal of the group was carried out with  piperidine−DMF (2:8) (2 x 3 min, 1 x 4 min, and 1 
x 5 min). Washings between deprotection, coupling, and final deprotecion steps were carried out in 
DMF (5 x 1 min) and DCM (5 x 1min) using 10 mL solvent/g resin for each wash. 
pNZ: Removal of the group was carried out unless indicated otherwise with 6 M SnCl2,1.6 mM 
HCl(dioxane), in DMF (2 x 30 min).  After that the resin was washed with DMF (3 x 30 s), 
DMF−H2O(3 x 30 s), THF−H2O (3 x 30 s), DMF (3 x 30 s), and DCM (3 x 30 s). 
Coupling of Fmoc-amino acids and handles were performed by adding the carboxylic acid reagent (4 
eq), and the coupling reagent [DIPCDI (4 eq) and HOBt (4 eq ), or HATU (3.8 eq) and DIEA (12 eq)] in 
DMF (0.5 mL) to the resin and the mixture left to stir for 60-90 min.   
In all cases, the course of the reactions was followed by ninhydrin test39 and the coupling repeated if 
the test gave positive.   
Peptide synthesis transformations and washes were performed at 25 ºC  unless indicated otherwise. 
Final Cleavage and Deprotection: The acidolytic cleavage was carried out with TFA−H2O−DCM 
(90:5:5) (10 mL/g of resin).  The TFA was removed by evaporation and the residue was taken with 
AcOH−H2O (7:3) and washed three times with CHCl3, and the aqueous phase lyophilized.   
Synthesis of H-Tyr-Phe-Gly-Gly-Leu-NH2 
Synthesis 1: Rink amide resin (50 mg, 0.66 mmol/g). CouplingsDIPCDI−HOBt method.. Then, the 
pNZ was removed and the resin was neutralized with DIEA−CH2Cl2 (1:9), washed with DCM (5 x 1 
min.), and DMF (5 x 1 min.) before performing the next coupling.  After final acydolitic cleavage and 
work up, the crude product was analyzed by HPLC (rt= 6.37 min. Gradient: from H2O (0.045% of TFA) 
to AcCN (0.036% of TFA), and HPLC-MS.  
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Synthesis 2: The same synthetic process as outline above was repeated but carrying out the removal of 
the pNZ at 50 ºC. 
Synthesis of  H-Ala-Leu-Ser-Tyr-Gly- Phe-NH2 
Rink amide resin (50 mg, 0.66 mmol/g). Couplings:  pNZ-amino acids (4 eq), HATU (3.8 eq) and 
DIEA (12 eq) in DMF (0.5 mL) were added to the resin and the reaction mixture was left to stir for 1 
hour.  Then, the pNZ group was removed and the resin was washed before performing the next coupling 
without previous neutralization.  After final acydolitic cleavage and work up, the crude product was 
analyzed by HPLC (rt= 6.05 min. Gradient: from H2O:AcCN (95:5) to H2O:AcCN  
(5:95) where H2O contains 0.045% of TFA and AcCN contains 0.036% of TFA) and HPLC-MS.  
Avoiding DKPs Formation 
Aminomethyl resin (100 mg, f = 1.2 mmol/g) was used as base resin.  Fmoc-L-Pro-OH (4 eq), DMAP 
(0.4 eq) and DIPCDI (4 eq) in DMF (1 mL) were added to the HO-AB-Leu-aminomethyl resin, which is 
a Wang type resin,40 and the reaction mixture was left to stir for 1 h.  After washing, the TosCl-PNBP 
test41 confirmed the correct coupling of the amino acid. Then Fmoc group was removed, the resin was 
divided in two parts and the peptides were synthesized. 
Fmoc synthesis: The Fmoc-D-Val-OH was incorporated using DIPCDI/HOBt mediated coupling, the 
Fmoc was removed, after washings the Fmoc-Phe-OH was incorporated using the same protocol, the 
Fmoc was removed and the amino acid analysis of an acid hydrolyzated indicated that the extension of 
side reaction has been of 100%.  
pNZ synthesis: pNZ-D-Val-OH was incorporated using DIPCDI/HOBt mediated coupling, the pNZ 
was removed, after washings the Fmoc-Phe-OH (4 eq), PyAOP (4 eq),42 and DIEA (8 eq) in DMF (0.5 
mL) were added and the reaction mixture was stirred for 1 h. After washing as indicated above, the 
ninhydrin test was negative. Then, the resin was washed and the amino acid analysis of an acid 
hydrolyzated indicated that the side reaction did not occur. 
Avoiding Aspartimide Formation 
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Rink amide resin (200 mg, 0.66 mmol/g) was used and the synthesis were carried out as outlined 
above using DIPCDI/HOBt mediated couplings.  After removal of the Fmoc group of the Gly, the resin 
was divided in two parts for the Fmoc and the pNZ synthesis. After acidolytic cleavage and work up, the 
crude were analyzed by HPLC (rt= 9.04 min. Gradient: from H2O to H2O-AcCN (7:3), where H2O 
contains 0.045 % of TFA and AcCN contains 0.036 % of TFA)  and HPLC-MS. 
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